Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-
related lung cancers continue to account for the majority of diagnoses, smoking rates have …

Anaplastic lymphoma kinase-rearranged lung cancer is associated with significant response
to crizotinib. However, resistance to crizotinib typically develops within 1-2 years. Preclinical …

Background Patients with lung cancer are at increased risk for venous thromboembolism
(VTE), particularly those receiving chemotherapy. It is estimated that 8% to 15% of patients …

Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and
squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is …

Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) have shown dramatic
efficacy in patients with ALK-rearranged lung cancer; however, complete response in these …

Several kinase fusions are established targetable drivers in lung cancers. However, rapid
and comprehensive detection remains challenging because of diverse partner genes and …

Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer
(NSCLC) is routinely evaluated by fluorescent in-situ hybridization (FISH) testing on biopsy …

Ciliated muconodular papillary tumor (CMPT) of the lung is an extremely rare peripheral
tumor of the lung. The pathogenesis of CMPT is still unknown, and its nature as a benign …

Lung adenocarcinoma has distinctive clinicopathological features that are related to specific
genetic alterations, including EGFR and KRAS mutations and ALK rearrangement …

Due to advances in the understanding of lung adenocarcinoma since the advent of its 2004
World Health System classification, an international multidisciplinary panel [sponsored by …